Patients report that cannabis puts arthritis into remission, so the Arthritis Society funds the research to find out if it’s true.
There’s good news for the 54 million people who suffer from arthritis: A study commissioned by The Arthritis Society is investigating avenues toward developing breakthrough therapies using medical cannabis.
Canadian researcher, Dr. Jason McDougall, received a Strategic Operating Grant from the organization to complete a three-year study on the ability of cannabis to effectively repair arthritic joints. McDougall is a professor of pharmacology and anesthesia at Dalhousie University in Halifax, Nova Scotia, and one of the world’s foremost pain researchers.
“People living with arthritis pain are looking for alternatives to improve their quality of life,” said Janet Yale, president and CEO of The Arthritis Society. “We need research to help answer the many important questions around medical cannabis and its use. Our goal is to give Canadians the ability to make informed choices about their treatment options and to give physicians evidence-based guidelines to make treatment recommendations for their patients. This project is an important step to achieving these goals.”
The research builds on previous work from Chinese scientists who found that not only do arthritic joints contain extremely high concentrations of CB2 receptors, but that those sites also suggest a pathway for treatment.
What is a CB2 receptor? In layman’s terms, CB2 is a molecule in the cell wall that acts as a doorway for cannabinoids to enter the cell. It’s the cell’s way of flagging down helpful particles that circulate past it during the day-to-day functioning of the body.
While the body produces its own endocannabinoids that can attach and work on a cell through CB2 receptors, cannabis-based medicine also has the ability to walk through the same door. Researchers believe this may be the reason why cannabis is effective in treating disorders like rheumatoid arthritis.
There are plenty of reasons to think so.
A study in the journal Philosophical Transactions of the Royal Society B found that the body’s endocannabinoid system releases antioxidants that help repair damaged cells when it becomes triggered by outside cannabinoids.
And anecdotal evidence, such as the story of a Maine woman whose use of cannabis smoothies led to so much relief that her rheumatoid arthritis symptoms went into remission, provide further thought-provoking justifications to delve deeper into the treatment possibilities of cannabis.
What’s more: businesses are jumping on the bandwagon. Canadian medical cannabis companies Aphria, Inc. and the Peace Naturals Project have each pledged $100,000 to the Arthritis Society in order to help foot the bill for Dr. McDougall’s research. When the market is bullish on new research, it’s a good sign for sufferers.
The reality is that cannabinoid receptors play a crucial role in the regulating the body’s immune system. What’s not clear is exactly how they operate. From a strictly biological perspective, auto-immune disorders like rheumatoid arthritis, and chronic disorders like osteoarthritis don’t make much sense. Why would the body attack itself or be unable repair such crucial functions, like joint dexterity? The discovery of cannabinoid receptors at inflammatory sites may provide an answer.
Thanks to a litany of previous works in this arena, McDougall’s team already knows that cannabis-based medicines act directly on CB2 sites and suppress inflammation and pain by mediating immune responses at the sites of inflammation. This suggests that the body’s reaching out for molecules to help it reconstruct its vital elements.
However, as our knowledge of the body’s endocannabinoid system grows, and we look further into the means by which cannabis-based medicines reduce inflammation and affect nerves, we’re likely to discover novel ways of treatment—and possible ways to reverse the long-lasting joint damage of arthritis.
While McDougall’s research has yet to be completed, the results are expected soon.